{
    "root": "15c77ad7-7edc-4c36-ba3f-3ef05dfb12dc",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Venlafaxine Hydrochloride",
    "value": "20250227",
    "ingredients": [
        {
            "name": "ETHYLCELLULOSE (20 MPA.S)",
            "code": "BJG0S321QY"
        },
        {
            "name": "HYPROMELLOSE 2910 (5 MPA.S)",
            "code": "R75537T0T4"
        },
        {
            "name": "SUCROSE",
            "code": "C151H8M554"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        },
        {
            "name": "GELATIN, UNSPECIFIED",
            "code": "2G86QN327L"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "POVIDONE, UNSPECIFIED",
            "code": "FZ989GH94E"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "SODIUM HYDROXIDE",
            "code": "55X04QC32I"
        },
        {
            "name": "FD&C RED NO. 40",
            "code": "WZB9127XOA"
        },
        {
            "name": "VENLAFAXINE HYDROCHLORIDE",
            "code": "7D7RX5A8MO"
        }
    ],
    "indications": "Venlafaxine hydrochloride extended-release capsules are indicated in adults for the treatment of:    • Major Depressive Disorder (MDD)    [    see Clinical Studies (14.1)]   \n                      • Generalized Anxiety Disorder (GAD)    [    see Clinical Studies (14.2)]   \n                      • Social Anxiety Disorder (SAD)    [    see Clinical Studies (14.3)]   \n                      • Panic Disorder (PD)    [    see Clinical Studies (14.4)]",
    "contraindications": "Indication Starting Dose Target Dose Maximum Dose MDD ( 2.2 ) 37.5 to 75 mg/day 75 mg/day 225 mg/day GAD ( 2.3 ) 37.5 to 75 mg/day 75 mg/day 225 mg/day SAD ( 2.4 ) 75 mg/day 75 mg/day 75 mg/day PD ( 2.5 ) 37.5 mg/day 75 mg/day 225 mg/day • Take once daily with food. Capsules should be taken whole; do not divide, crush, chew, or dissolve ( 2.1 ). • When discontinuing treatment, reduce the dose gradually ( 2.10 , 5.7 ). • Renal impairment: reduce the total daily dose by 25% to 50% in patients with renal impairment. Reduce the total daily dose by 50% or more in patients undergoing dialysis or with severe renal impairment ( 2.9 ). • Hepatic impairment: reduce the daily dose by 50% in patients with mild to moderate hepatic impairment. In patients with severe hepatic impairment or hepatic cirrhosis, it may be necessary to reduce the dose by more than 50% ( 2.8 ).",
    "warningsAndPrecautions": "Venlafaxine hydrochloride extended-release capsules, USP are available as follows:\n                  \n                      • 75 mg capsules are size \"1\" peach colour hard gelatin capsules filled with white to off white pellets and imprinted with \"G\" on cap, \"75\" on body with red ink.  \n                  Bottles of 30          NDC 68788-8837-3\n                  Bottles of 60          NDC 68788-8837-6\n                  Bottles of 90          NDC 68788-8837-9\n                  \n                     Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].",
    "adverseReactions": "Venlafaxine hydrochloride extended-release capsules are contraindicated in patients:\n                  \n                     \n                        •with known hypersensitivity to venlafaxine hydrochloride, desvenlafaxine succinate or to any excipients in the formulation     [see      Adverse Reactions (6.2)].    \n                     \n                     \n                        •taking, or within 14 days of stopping, MAOIs (including the MAOIs linezolid and intravenous methylene blue) because of the risk of serotonin syndrome     [see      Dosage and Administration (2.11),\n                           Warnings and Precautions (5.2), and      \n                        ]."
}